Inclusion on the list of medicines approved for hospital use.
-
Clinical Benefit
Substantial
The actual benefit provided by SAVENE in the treatment of anthracycline extravasation is substantial.
Clinical Added Value
moderate
In light of the absence of treatment alternatives and despite the methodological inadequacies of the studies contained in the file, the Transparency Committee considers that SAVENE provides a moderate improvement in actual benefit (IAB III) in the treatment of anthracycline extravasations.